Effects of Antiretroviral Drugs for Prevention of HIV-Mother-to-Child Transmission on Hematological Parameters and Hemoglobin Synthesis in HIV-Uninfected Newborns with and without Thalassemia Carrier
Rotjanee Wongnoi, Peninnah Oberdorfer, Pannee Sirivatanapa, Chotiros Phanpong and Sakorn Pornprasert
Affiliation: Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang-Mai University, 110 Intawaroros Road, Chiang-Mai, 50200, Thailand.
Keywords: ARV drugs, HIV, hemoglobin synthesis, hematological parameters, newborn.
The effects of antiretroviral (ARV) drugs administered to HIV-infected pregnancy on hematological parameters
and hemoglobin (Hb) synthesis in ARV-exposed newborns with and without thalassemia carrier and of ARV drugs in
worsening anemia in thalassemia carrier newborns are not well understood. Cord blood samples were collected from
newborns of HIV-infected and -uninfected pregnancies. Hematological parameters and hemoglobin typing were analyzed
by automated blood counter and capillary electrophoresis (CE), respectively. In the group of thalassemia carrier, the
ARV-exposed newborns had significantly lower mean levels of red blood cell counts and hematocrit and had significantly
higher mean levels of MCH than the ARV-unexposed newborns. Similar results were found in the group of newborns
without thalassemia carrier. There were no statistical differences in mean levels of Hb-A2, Hb-A, Hb-F and Hb-E (when
applicable) in ARV-exposed and -unexposed newborns either with or without thalassemia carrier. However, ARVexposed
newborns who were thalassemia carriers had the lowest levels of hemoglobin and hematocrit when compared to
the other groups. Therefore, ARV drugs used for prevention of HIV-mother-to-child transmission (HIV-MTCT) altered
hematological parameters but did not affect hemoglobin synthesis in newborns with and without thalassemia carrier.
However, thalassemia and ARV drugs might have synergetic effect in inducing severe anemia.
Rights & PermissionsPrintExport